Top stocks: Morgans' Raymond Chan shares his tips for the dip

Switzer2025-11-20

Raymond Chan, head of research at Morgans, joined Switzer Investing TV this week and gave his verdict on a handful of market movers. Here’s where he’s seeing value, what’s on his “wait and see” list, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584764169?lang=en_US&edition=fundamental","thumbnail":"https://switzer.com.au/wp-content/uploads/Raymond_chan_switzer_daily.png","is_english":true,"pubTime":"2025-11-20 05:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584764169","market":"us","top_or_hot":-1,"title":"Top stocks: Morgans' Raymond Chan shares his tips for the dip","media":"Switzer","content":"<div>\n<p>Raymond Chan, head of research at Morgans, joined Switzer Investing TV this week and gave his verdict on a handful of market movers. Here’s where he’s seeing value, what’s on his “wait and see” list, ...</p>\n\n<a href=\"https://switzer.com.au/the-experts/luke-hopewell/top-stocks-morgans-raymond-chan-shares-his-tips-for-the-dip/\">Source Link</a>\n\n</div>\n","source":"switzer_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top stocks: Morgans' Raymond Chan shares his tips for the dip</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop stocks: Morgans' Raymond Chan shares his tips for the dip\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-20 05:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://switzer.com.au/the-experts/luke-hopewell/top-stocks-morgans-raymond-chan-shares-his-tips-for-the-dip/><strong>Switzer</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Raymond Chan, head of research at Morgans, joined Switzer Investing TV this week and gave his verdict on a handful of market movers. Here’s where he’s seeing value, what’s on his “wait and see” list, ...</p>\n\n<a href=\"https://switzer.com.au/the-experts/luke-hopewell/top-stocks-morgans-raymond-chan-shares-his-tips-for-the-dip/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1169590202.USD","symbol_name":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://switzer.com.au/the-experts/luke-hopewell/top-stocks-morgans-raymond-chan-shares-his-tips-for-the-dip/","article_id":"2584764169","we_media_id":null,"thumbnails":["https://switzer.com.au/wp-content/uploads/Raymond_chan_switzer_daily.png"],"rights":{"source":"switzer_stock","url":"https://switzer.com.au/the-experts/luke-hopewell/top-stocks-morgans-raymond-chan-shares-his-tips-for-the-dip/","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2584764169","pubTimestamp":1763586478,"columns":[],"sourceInfo":{"source_id":"switzer_stock","name":"Switzer"},"weMediaInfo":null,"summary":"Raymond Chan, head of research at Morgans, has given us his verdict on a handful of market movers. Here’s where he’s seeing value, what’s on his “wait and see” list, and the stocks that might need a little more patience.","collect":0,"end_time":0,"defaultTopTitle":"switzer.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK4588":"碎股","BK7155":"工业房地产信托","LU0124384867.USD":"贝莱德新能源基金A2","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","BK4096":"电气部件与设备","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","NXT":"NEXTracker Inc","NXT.AU":"NEXTDC LTD","XRO.AU":"XERO LTD","LU0302445910.USD":"SCHRODER ISF GLOBAL CLIMATE CHANGE EQUITY \"A\" ACC","LU0724618433.USD":"BGF NEW ENERGY \"A4\" (USD) INC","BK7043":"互联网服务与基础架构","BK7508":"医药生物股","BK7501":"新冠治疗股","BK7510":"REITs概念","BK4086":"建筑产品","BK7503":"科技股","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","LU1983299162.USD":"SCHRODER ISF GLOBAL ENERGY TRANSITION \"A\" (USD) ACC","BK4212":"包装食品与肉类","LU2249611893.SGD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (SGD) ACC","PME":"平潭海洋实业有限公司","BK7511":"ESG概念","LU2357125470.USD":"BNP PARIBAS ENERGY TRANSITION \"CLASSIC RH\" (USDHDG) ACC","BK4596":"哈里斯概念","LU2275660780.HKD":"SCHRODER ISF GLOBAL CLIMATE CHANGE EQUITY \"A\" (HKD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","CSL.AU":"CSL LIMITED","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7094":"医疗保健技术","PME.AU":"PRO MEDICUS LTD","BK7016":"应用软件","BK4585":"ETF&股票定投概念","LU0823414551.USD":"BNP PARIBAS ENERGY TRANSITION \"C\" (USD) INC","BK7099":"工业房地产投资信托","LU2506951792.HKD":"BNP PARIBAS ENERGY TRANSITION \"CRH\" (HKDHDG)       ACC","LU2298322129.HKD":"BGF SUSTAINABLE ENERGY \"A2\" (HKDHDG) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","360.AU":"LIFE360 INC-CDI","GMG.AU":"GOODMAN GROUP","LU2294711713.HKD":"BNP PARIBAS ENERGY TRANSITION \"C\" (HKD) ACC","BK7067":"生物科技","LU0823414478.USD":"法巴经典能源转换基金","CSL":"卡莱尔伙伴"},"translate_title":"热门股票：摩根士丹利的Raymond Chan分享了他的下跌技巧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":1,"PME.AU":1,"XRO.AU":1,"NXT":1,"CSL":1,"GMG.AU":1,"360.AU":1,"NXT.AU":1,"PME":1},"content_text":"Raymond Chan, head of research at Morgans, joined Switzer Investing TV this week and gave his verdict on a handful of market movers. Here’s where he’s seeing value, what’s on his “wait and see” list, and the stocks that might need a little more patience.\nJust remember, this isn’t financial advice—do your own homework and talk to a pro before acting on anything here.\nThe Buy List\nCSL (CSL)\nChan is unambiguously positive on CSL, viewing the current price as an opportunity with limited downside. He points to strength in plasma-based medicines and a discount valuation versus history:\n“I think we have a buy, on CSL. I think at the current level, the downside risks, limited… The key part is now the plasma-driven drugs division, which is almost 70% of the total revenue that we think will continue to grow, quite well… At the moment, they are trading at a P/E which is at a discount to the long-term average. We don’t think there’s too much of the downside risk for CSL at this stage. So for us it’s a buy.”\nWhile the vaccine division faces some challenges, Chan believes the core business is strong and that current levels represent good value.\nGoodman Group (GMG)\nA familiar favourite, Goodman gets Chan’s endorsement—especially on recent share price weakness. He sees the company’s low gearing as a buffer against volatility:\n“Goodman I actually like this name at the current price… Goodman on the headline, the gearing is very low… Also, the stock’s has meaningfully pulled back from its recent high… I think what we need for Goodman is in the next set of update is they start to upgrade the outlook a little bit, and the market will start to love Goodman again. So I think the current pullback will likely be a buying opportunity for Goodman especially is below $30.”\nPro Medicus (PME)\nWhile he prefers to buy PME on further weakness, Chan is fundamentally positive and highlights the company’s market position and contract “stickiness”:\n“We a[n]alyst always like this company… the growth, suddenly, meaningfully. And in the US, they have a market share… those contracts are very sticky. That’s what we like… We like this company that, you know, it is suddenly, worth look at, you know, if there’s price weakness on Pro Medicus, in the current market.”\nFor Chan, Pro Medicus remains a top pick if you can get it a little cheaper.\nThe ‘Maybe’ List\nSometimes, great companies just need a little more time—or a little more clarity. Here’s where Chan isn’t rushing in, but isn’t closing the door either.\nNEXTDC (NXT)\nChan isn’t ready to call NXT a buy at current levels, citing valuation and sector sentiment:\n“NextDC… at the current price, they suddenly [are] not cheap… the company [has] a strong track record… Now… they’re partnering with capital partner to develop the offshore area such as Japan… if the sentiment move[s] toward data centre again… we may see a bounce… but at the moment, NextDC is likely to trade sideways before a more clear direction… So it’s not a screaming buy at the moment, but further weakness likely to create opportunity.”\nChan sees NXT as a watchlist name unless there’s a price pullback.\nXero (XRO)\nWhile growth investors might find Xero appealing, Chan is cautious about the near-term outlook due to its US expansion and ongoing cash burn:\n“Xero is a little bit interesting… Xero is a growth company. When they make the acquisition… with aim to expand into… the US market… it will probably would take some time before Xero can deliver to the long term plan, which I think is important for them. For us, I think at this stage, we’ll have a hold recommendation on Xero.”\nFor Chan, the thesis is long-term but requires patience and a strong stomach for volatility.\nLife360 (360)\nNo formal coverage, but Chan shared an anecdote and seemed open to the company’s growth prospects, referencing the product’s “playoff certainty” for families:\n“Life360… we don’t have coverage on the company, but my dog is using it. We use it to track where he’s going… We think this a playoff certainty.”\nWhile not an outright buy, there’s a nod of approval to the product’s value and potential.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584764169","isCrawlerRequest":true}